Focused On-demand Library for Potassium voltage-gated channel subfamily D member 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9NZV8

UPID:

KCND2_HUMAN

Alternative names:

Voltage-gated potassium channel subunit Kv4.2

Alternative UPACC:

Q9NZV8; O95012; O95021; Q2TBD3; Q9UBY7; Q9UN98; Q9UNH9

Background:

The Potassium voltage-gated channel subfamily D member 2, also known as Kv4.2, is crucial for mediating transmembrane potassium transport in excitable membranes, predominantly in the brain. It plays a pivotal role in regulating neuronal excitability, action potential firing, and contributes to the circadian rhythm of locomotor activity. Kv4.2 forms tetrameric potassium-selective channels, functioning in both homotetrameric and heterotetrameric forms, with its activity modulated by interaction with KCNIP regulatory subunits.

Therapeutic significance:

Understanding the role of Potassium voltage-gated channel subfamily D member 2 could open doors to potential therapeutic strategies.